ロード中...
Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of rituximab (RTX) [Roche] to submit evidence for the clinical and cost effectiveness of RTX as first-line maintenance treatment for patients with follicular non-Hodgkin’s lymphoma (fNHL) whose disease has resp...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing AG
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3654180/ https://ncbi.nlm.nih.gov/pubmed/23576017 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-013-0043-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|